Cathie Wood is long BEAM, But I will be Strong Short #CathieWood
Baught this stock...I analyzed it....and …...well....I would do exact the opposite......
But why?
Technical Analysis
Let forget eveything you know about technical analysis, and let together tell this story....logically..
At
76-71 USD AGGRESSIVE SELLERS FORCED THE PICE DOWN
29,72 USD BUYERS DEFENDED THIS Area(ZONE) as well the sellers took partial profits, and accumulated their positions ,but this time more powerfully and aggressive at 64-61USD zone
THE PRICE MOVED DOWN, Institutional buyers took patial profits,(the best decision they could do OTHERWISE THEY WOULD LOSE ALL THIER PROFITS LOOK AT THE PICE OF TODAY
The retail traders who followed the news and the hype baught Beam hoping that the share prce will fly to the moon,but......
At 64-61 who is waiting there?
YES THE AGGRESSIVE SELLERS!!!!
NOW THEY FORCED MUCH MORE ORDERS TO SEND THE PRICE To the....where we are now....
Bad for the buyers...Some buyers took profits, some took losses, and to compensate thier losses, they started to sell short the market....
At 28,80(YELLOW LINE) we are now at the weak support(low volume) The market could make a retracement to 44,94USD
where the sellers and BEARS are waiting of them.....to do what? Well you know it.....
Otherwise...more selles (former retail trades bulls) could decide to sell the maket from here....
WE HAVE A LONG DISTANCE TO GO DEEPER....
Targets short
13,75
8,68
3,82
1,25
.
.
Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (BEAM 1.11%). The gene-editing stock currently ranks as the ETF's 18th-largest holding. It's also the ninth-largest position in Wood's ARK Genomic Revolution ETF.
Beam Therapeutics is a pioneer in base editing. Most types of gene editing involve double-strand breaks in DNA that can cause random unwanted insertions and deletions. Base editing is highly precise, with no double-strand breaks and no off-target genetic changes. Because of these characteristics, base editing holds tremendous promise as a method for developing therapies targeting genetic diseases and "off the shelf" cell therapies for treating cancer.
So far, Beam has advanced two base-editing candidates into clinical testing. It's evaluating BEAM-101 as a treatment for two rare blood disorders: sickle cell disease and beta-thalassemia. And the company expects to begin dosing patients in a phase 1 study of experimental cancer cell therapy BEAM-201 by mid-2023.
Those two programs could be joined by two others soon. Beam hopes to submit for regulatory approvals to start clinical studies of BEAM-301 as a treatment for glycogen storage disease type 1a and BEAM-302 as a treatment for severe alpha-1 antitrypsin deficiency by early 2024.
The company has a long way to go. But if its base-editing programs prove to be safe and effective, Beam could be a massive winner.
